There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Edwards Lifesciences (EW) and IQVIA Holdings Inc (IQV) with bullish sentiments.
Edwards Lifesciences (EW)
Morgan Stanley analyst David Lewis maintained a Buy rating on Edwards Lifesciences today and set a price target of $197. The company’s shares closed on Friday at $179.75, close to its 52-week high of $181.43.
According to TipRanks.com, Lewis is a 5-star analyst with an average return of 11.2% and a 74.8% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Irhythm Technologies.
Edwards Lifesciences has an analyst consensus of Moderate Buy, with a price target consensus of $180.60, a 0.5% upside from current levels. In a report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $215 price target.
See today’s analyst top recommended stocks >>
IQVIA Holdings Inc (IQV)
In a report released today, Jack Meehan from Barclays maintained a Buy rating on IQVIA Holdings Inc, with a price target of $167. The company’s shares closed on Friday at $141.53, close to its 52-week high of $144.77.
According to TipRanks.com, Meehan is a 4-star analyst with an average return of 7.2% and a 64.4% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, Syneos Health Inc, and Myriad Genetics.
Currently, the analyst consensus on IQVIA Holdings Inc is a Strong Buy with an average price target of $157.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
